Univariate analysis of association with overall survival
| Univariate analysis . | Actuarial probability . | P . |
|---|---|---|
| D sex (male vs female) | 51% vs 59% | .9 |
| R sex (male vs female) | 53% vs 57% | .8 |
| Sex-pairing match (yes vs no) | 62% vs 44% | .04 |
| Female D to male R (yes vs no) | 43% vs 56% | .24 |
| Male D to female R (yes vs no) | 44% vs 58% | .16 |
| D median age (≤ 40 years vs > 40 years) | 63% vs 46% | .16 |
| R median age (≤ 42 years vs > 42 years) | 65% vs 45% | .1 |
| CMV serology | ||
| D and R negative (yes vs no) | 80% vs 48% | .05 |
| D negative (yes vs no) | 65% vs 46% | .24 |
| R negative (yes vs no) | 65% vs 49% | .23 |
| Diagnosis | ||
| AML/ALL/MDS | 50% | |
| CML | 57% | |
| NHL/CLL/MM | 63% log-rank χ2 = 0.5 | .8 |
| Stage of disease (early vs advanced) | 60% vs 44% | .16 |
| CD34+ cells × 106/kg | ||
| 1-3, n = 28 | 75% | |
| > 3 to 4.7, n = 28 | 49% | |
| > 4.7-14.3, n = 28 | 34% log-rank χ2 = 5.5 | .05 |
| CD34+ cells × 106/kg (1-3 vs > 3) | 75% vs 42% | .01 |
| CD3+ cells × 106/kg | ||
| ≤ 0.28, n = 28 | 47% | |
| > 0.28 to 0.4, n = 30 | 50% | |
| > 0.4, n = 26 | 55% log-rank χ2 = 0.47 | .8 |
| CD34+ selection method (biot-av vs immunomagn) | 58% vs 46% | .4 |
| Cryopreservation (no vs yes) | 55% vs 54% | .7 |
| GVHD prophylaxis (CsA + PDN vs CsA) | 65% vs 45% | .2 |
| Univariate analysis . | Actuarial probability . | P . |
|---|---|---|
| D sex (male vs female) | 51% vs 59% | .9 |
| R sex (male vs female) | 53% vs 57% | .8 |
| Sex-pairing match (yes vs no) | 62% vs 44% | .04 |
| Female D to male R (yes vs no) | 43% vs 56% | .24 |
| Male D to female R (yes vs no) | 44% vs 58% | .16 |
| D median age (≤ 40 years vs > 40 years) | 63% vs 46% | .16 |
| R median age (≤ 42 years vs > 42 years) | 65% vs 45% | .1 |
| CMV serology | ||
| D and R negative (yes vs no) | 80% vs 48% | .05 |
| D negative (yes vs no) | 65% vs 46% | .24 |
| R negative (yes vs no) | 65% vs 49% | .23 |
| Diagnosis | ||
| AML/ALL/MDS | 50% | |
| CML | 57% | |
| NHL/CLL/MM | 63% log-rank χ2 = 0.5 | .8 |
| Stage of disease (early vs advanced) | 60% vs 44% | .16 |
| CD34+ cells × 106/kg | ||
| 1-3, n = 28 | 75% | |
| > 3 to 4.7, n = 28 | 49% | |
| > 4.7-14.3, n = 28 | 34% log-rank χ2 = 5.5 | .05 |
| CD34+ cells × 106/kg (1-3 vs > 3) | 75% vs 42% | .01 |
| CD3+ cells × 106/kg | ||
| ≤ 0.28, n = 28 | 47% | |
| > 0.28 to 0.4, n = 30 | 50% | |
| > 0.4, n = 26 | 55% log-rank χ2 = 0.47 | .8 |
| CD34+ selection method (biot-av vs immunomagn) | 58% vs 46% | .4 |
| Cryopreservation (no vs yes) | 55% vs 54% | .7 |
| GVHD prophylaxis (CsA + PDN vs CsA) | 65% vs 45% | .2 |
D indicates donor; R, recipient; CMV, cytomegalovirus; AML, acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodisplastic syndrome; CML, chronic myeloid leukemia; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; biot-av, immunoadsorption biotin-avidin column; immunomagn, immunomagnetic beads; GVHD, graft-versus-host disease; CsA, cyclosporine A; PDN, methylprednisolone.